Logo

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Share this

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Shots:

  • The P-Ib/II trial evaluates the safety and preliminary efficacy of onvansertib + Folfiri and Avastin in 2L treatment of patients with KRAS-mutated mCRC
  • As of July 2- 2021- 42% patients achieved a partial response at RP2D (15 mg/m2 dose); confirmed PR (37%); ORR (5-13%); mPFS has not yet reached. Additionally- 38% patients achieved an initial PR who treated at all dose levels (12 mg/m2- 15 mg/m2- 18 mg/m2); confirmed PR (31%); mPFS (9.4mos.) across all response-evaluable patients
  • Additionally- partial responses were observed across different KRAS mutation variants. The combination is well-tolerated and showed the synergistic effect

| Ref: Cardiff Oncology | Image: PharmaLive

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions